A Study of RG1662 in Individuals With Down Syndrome
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This multi-center, randomized double-blind, placebo-controlled study will assess the safety
and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be
randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated
time on study treatment is 38 days.